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Introduction {#sec005}
============

Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, with the prevalence increasing progressively with age \[[@pone.0125257.ref001]\]. A national survey based on health insurance data in Taiwan showed hospitalizations due to AF increased from 91 per 100,000 to 150 per 100,000 between 1997 and 2002 \[[@pone.0125257.ref002],[@pone.0125257.ref003]\]. AF is an important risk factor for stroke, which confers a major healthcare burden on acute or long-term medical care, as well as on patient disability\[[@pone.0125257.ref004],[@pone.0125257.ref005]\].

Various stroke risk stratification schemes, including the CHADS~2~\[[@pone.0125257.ref006]\] and CHA~2~DS~2~-VASc\[[@pone.0125257.ref007]\] scores for stroke risk, and the HAS-BLED score for bleeding risk, have been used to aid risk prediction in AF although some ethnic and gender differences may be evident \[[@pone.0125257.ref008]--[@pone.0125257.ref010]\].

Stroke prevention in AF requires the use of oral anticoagulation (OAC) with antiplatelet therapy only having a weak efficacy\[[@pone.0125257.ref011]\]. Both OAC and antiplatelet drugs confer an increased risk of bleeding, which is accentuated by its combined use amongst AF patients\[[@pone.0125257.ref012]--[@pone.0125257.ref014]\]. However, the balance between efficacy and safety with OAC also depends on the quality of INR control, as reflected by the average time in therapeutic range (TTR) \[[@pone.0125257.ref015],[@pone.0125257.ref016]\], with the recommended TTR being \>70%\[[@pone.0125257.ref017]\]. In many countries, the average TTR is poor, and in a recent randomized trial, the average TTR in Taiwan was only 44%\[[@pone.0125257.ref018]\].

One small hospital based study from Beijing, China reported that stroke and bleeding rates were not different between warfarin, aspirin and untreated patients, reflecting that many warfarin-treated patients did not have regular access to anticoagulation monitoring and offering opportunities for improved stroke prevention with the novel OAC drugs\[[@pone.0125257.ref019]\]. We are unaware of any large cohorts comparing stroke and bleeding risk in the Far East, where OAC control with warfarin may be suboptimal. If the findings from the paper by Guo et al\[[@pone.0125257.ref019]\] were replicated in a large nationwide cohort, this would have major implications for missed opportunities for stroke prevention in AF, as well as important healthcare cost and public health implications.

In this study, we investigated stroke and bleeding rates in a national representative population amongst AF patients treated with OAC (warfarin), antiplatelet drugs as monotherapy and as combination therapy, compared to no antithrombotic therapy. Second, we assessed event rates according to antithrombotic therapy use, by stroke and bleeding risk strata, using established risk scoring systems, that is, CHADS~2~ and CHA~2~DS~2~-VASc for stroke risk, and the HAS-BLED score for bleeding risk.

Methods {#sec006}
=======

Data sources and searches {#sec007}
-------------------------

This study used a subset of National Health Insurance Research Database (NHIRD), the Longitudinal Health Insurance Database of 2000, which contains claims data of a randomly sampled cohort of one million people enrolled in the Taiwan National Health Insurance program during 1996--2000. The health insurance program has covered 99% or more of Taiwanese population and contracted more than 90% of healthcare institutions in Taiwan. We obtained the original claim data that included inpatient records, ambulatory care records, contracted pharmacies records and registries for beneficiaries. The Institutional Review Board in National Taiwan University Hospital approved the study protocol. The patient records/information was anonymized and de-identified prior to analysis and the informed consent was waived.

Patients had a first diagnosis for AF (the index admission) during 1999--2010 was considered as follows: the first diagnosis for AF: the presence of at least one inpatient claim with an ICD-9-CM code 427.3 in any one of up to 5 diagnostic codes or at least two outpatient claims with an ICD-9-CM code 427.3 in any one of up to 3 diagnostic codes. The date of diagnosis was defined as the index date. The accuracy of the ICD-9-CM codes for AF has been validated by medical chart review \[[@pone.0125257.ref020]\]; of patients who had an AF diagnosis by ICD-9-CM codes and used medications that might be prescribed to AF patients, 98% and 96% with AF recorded by either electrocardiogram or 24-hour Holter monitoring in a medical center and community teaching hospital, respectively. The exclusion criteria included the following: age at index date \<18 years, patients who died during the index admission, patients with rheumatic heart disease (ICD-9-CM codes 393--398 in any one of the five positions on at least one inpatient claims or in any one of the three positions on at least two outpatient claims), and patients who died during the index admission.

We defined antithrombotic drug exposure into 8 groups based on prescription after the index date: (i) OAC (essentially warfarin) monotherapy; (ii) aspirin monotherapy; (iii) clopidogrel monotherapy; (iv) aspirin + clopidogrel; (v) warfarin + aspirin; (vi) warfarin + clopidogrel; (vii) warfarin + aspirin +clopidogrel; and (viii) no antithrombotic therapy (ie. never users of warfarin, aspirin, clopidogrel). We calculated the usage according to the prescription history: 'monotherapy' was defined as group (1) to group (iii); 'combination therapy' was defined as group (iv) to group (vii). We defined 'continuous use' if the number of discontinued days was less than 7 days.

We defined the comorbidity histories, drug usage codes according to ICD-9-CM codes as the [S1 Table](#pone.0125257.s001){ref-type="supplementary-material"}. The definitions for the CHADS~2~, CHA~2~DS~2~-VASc and HAS-BLED scores were listed according to the clinical status within 2 years of the index date ([S2 Table](#pone.0125257.s002){ref-type="supplementary-material"}).

Outcome Measurements {#sec008}
--------------------

The follow-up duration began on the index date (or discharge date of index admission) and lasted until the "outcome" diagnosis, withdrawal from National Health Insurance, or December 31, 2010, whichever came first. We defined the following outcomes: (i) bleeding was defined as hospital admission for bleeding, including gastrointestinal, intracranial, urinary tract and airway bleeding episodes in the follow-up duration; (ii) hemorrhagic stroke: admission for hemorrhagic stroke (ICD9CM codes 431--432) in the follow-up duration; and (iii) ischemic stroke defined as admission for ischemic stroke (ICD9CM codes 433--437) in the follow-up duration.

Statistical analysis {#sec009}
--------------------

Demographic and clinical characteristics of the study participants were listed according to various therapy groups and were compared by ANOVA for continuous variables and by the chi-square test for categorical data. We calculated the incidence rate (per 1000 person-years) by dividing numbers of events of bleeding and stroke events with person-years of exposure to each group. Due to time varying nature of drug exposure, we defined the duration of specific drug exposure as days of use for each prescription from database at ambulatory care, and contracted pharmacies, but not at inpatient records because data of days of use of each prescription were not available.

We used multivariable models to estimate the relative risk (RR) and 95% confidence interval (CI) by Cox proportional hazards model with drug exposure as a time-varying covariate to assess the association between various groups and bleeding as well as stroke events. We used the single anticoagulant group (warfarin monotherapy) as the reference group\[[@pone.0125257.ref013]\] and adjusted for age, gender and comorbidity status, including history of ischemic heart, hypertension, ischemic stroke, heart failure, diabetes, liver disease, renal failure, malignancy, bleeding, and drug history of aspirin, warfarin and clopidogrel usage which were defined before index atrial fibrillation date. Moreover, we calculated the numbers and crude incidence rates of ischemic stroke and bleeding events according to the categories of CHADS~2~, CHA~2~DS~2~-VASc and HAS-BLED scores among various drug exposure groups to evaluate potential effects of drug treatment on the impact of risk stratification. All data analyses were performed using SAS version 9.3 (SAS Institute Inc., Carey, NC).

Results {#sec010}
=======

We included 10384 patients (57.2% male; mean age 67.8 years) with first-time AF diagnosis and live at discharge between 1999 and 2010 \[[Table 1](#pone.0125257.t001){ref-type="table"}\]. Compared with those treated with warfarin therapy, patients taking aspirin and clopidogrel were older and more likely to be male, and to have a history of ischemic heart disease, heart failure, hypertension, ischemic stroke, diabetes, renal failure, and history of bleeding, including gastrointestinal, intracranial and urinary track bleeding, and amiodarone use.

10.1371/journal.pone.0125257.t001

###### Study cohort and comorbidities at 2 years before index AF.

![](pone.0125257.t001){#pone.0125257.t001g}

  Name                                                                             Total        Warfarin      Aspirin      Clopidogrel   Aspirin+ Clopidogrel   Warfarin + Aspirin   Warfarin + Clopidogrel   Warfarin + Aspirin+ Clopidogrel   None
  -------------------------------------------------------------------------------- ------------ ------------- ------------ ------------- ---------------------- -------------------- ------------------------ --------------------------------- ------------
  Patients, total n (%)                                                            10384        1941(18.7)    7237(12.5)   1298 (12.5)   1369 (13.2)            1277 (12.3)          205 (2.0)                196 (1.9)                         2408(23.2)
  Age, yr                                                                          67.8(13.2)   67.4(12.1)    68.8(10.2)   72(12.0)      70.8(10.5)             68.3(10.7)           69.5(10.0)               68.2(9.1)                         65.1(12.2)
  Men, n (%)                                                                       5915(57.2)   1107 (57.0)   4168(57.6)   756(58.2)     845(61.7)              755(59.1)            124(60.5)                132(67.3)                         1333(55.4)
  Women, n (%)                                                                     4424(42.8)   834 (43.0)    3069(42.4)   542(41.8)     524(38.2)              522(40.9)            81(39.5)                 64(32.7)                          1075(44.6)
  Comorbidities, n (%) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                   
      Acute MI                                                                     37(0.4)      9(0.5)        25(0.4)      9(0.7)        16(1.2)                5(0.4)               2(1.0)                   2(1.0)                            6(0.3)
      Ischemic heart [^b^](#t001fn002){ref-type="table-fn"}                        789 (7.6)    120(6.2)      574(7.9)     184(14.2)     207(15.1)              99(7.8)              28(13.7)                 27(13.8)                          148(6.2)
      Heart failure [^c^](#t001fn003){ref-type="table-fn"}                         320(3.1)     78(4.0)       291(4.0)     74(5.7)       77(5.6)                48(3.8)              8(3.9)                   12(6.1)                           133(5.5)
      Hypertension                                                                 1667(16.5)   238(12.3)     1136(15.7)   286(22.0)     307(22.4)              177(13.9)            34(17.0)                 41(20.9)                          401(16.7)
      Ischemic stroke                                                              634(6.1)     97(5.0)       427(5.9)     109(8.4)      102(7.5)               82(6.4)              19(9.3)                  18(9.2)                           158(6.7)
      Diabetes                                                                     966(9.3)     125(6.4)      622(8.6)     197(15.2)     197(14.4)              88(6.9)              23(11.2)                 31(15.8)                          254(10.6)
      Liver disease                                                                267(2.6)     32(1.7)       164(2.3)     28(2.2)       23(1.7)                16(1.3)              3(1.5)                   1(0.5)                            94(3.9)
      Renal failure                                                                210(2.0)     21(1.1)       119(1.6)     37(2.9)       39(2.9)                8(0.6)               2(1.0)                   3(1.5)                            76(3.2)
      Malignancy                                                                   311(3.0)     21(1.1)       136(1.9)     34(2.6)       24(1.8)                9(0.7)               3(1.5)                   3(1.5)                            150(6.2)
      Bleeding                                                                     203(2.0)     23(1.2)       112(1.6)     28(2.2)       31(2.3)                13(1.0)              4(2.0)                   2(1.0)                            83(3.5)
          Gastrointestinal bleeding [^d^](#t001fn004){ref-type="table-fn"}         40(0.4)      6(0.3)        21(0.3)      7(0.5)        8(0.6)                 2(0.0)               1(0.5)                   1(0.5)                            18(0.8)
          Gastrointestinal bleeding [^e^](#t001fn005){ref-type="table-fn"}         92(0.9)      11(0.6)       49(0.7)      16(1.2)       17(1.2)                6(0.5)               3(1.5)                   1(0.5)                            40(1.7)
          Intracranial bleeding                                                    54(0.5)      6(0.3)        30(0.4)      8(0.6)        9(0.6)                 5(0.4)               1(0.5)                   0(0)                              23(1.0)
          Urinary tract bleeding                                                   44(0.4)      4(0.2)        24(0.3)      4(0.3)        5(0.4)                 1(0.1)               0(0)                     0(0)                              17(0.7)
          Airway bleeding                                                          13(0.1)      2(0.1)        9(0.1)       0(0)          0(0)                   1(0.1)               0(0)                     1(0.5)                            3(0.1)
  Previous antithrombotic treatment, n (%)[^f^](#t001fn006){ref-type="table-fn"}                                                                                                                                                                
      Aspirin                                                                      5650(54.4)   1071(55.2)    4698(64.9)   800(61.6)     957(69.9)              879(68.8)            111(54.2)                129(65.8)                         599(24.9)
      Warfarin                                                                     946(9.1)     726(37.4)     574(7.9)     127(9.8)      112(8.2)               379(30.0)            59(28.8)                 62(31.6)                          54(2.2)
      Clopidogrel                                                                  773(7.4)     112(5.8)      465(6.4)     361(27.8)     328(24.0)              79(6.2)              46(22.4)                 36(18.4)                          100(4.2)
  Antiarrhythmic drug treatment, n (%)                                                                                                                                                                                                          
      Amiodarone                                                                   2502(24.1)   360(18.5)     1509(20.9)   295(22.7)     241(17.6)              164(12.8)            25(12.2)                 14(7.1)                           751(31.2)
      Propafenone                                                                  643(6.1)     310(16.0)     233(3.2)     179(13.8)     356(26.0)              263(20.6)            104(50.7)                13(6.6)                           79(3.3)
      Sotalol                                                                      553(5.3)     142(7.3)      154(2.1)     123(9.5)      234(17.1)              347(27.2)            98(47.8)                 9(4.6)                            99(4.1)

a: Comorbidities(Acute MI, Ischemic heart ^b^ Heart failure ^c^, Hypertension, Ischemic stroke, Diabetes, Liver disease, Renal failure, Malignancy, Bleeding, Gastrointestinal bleeding ^d^, Gastrointestinal bleeding ^e^, Intracranial bleeding, Urinary tract bleeding and Airway bleeding) were defined before index AF (including index admission date) were defined 2 years before index AF (including index admission date).

b: Ischemic heart disease was defined as having treatments of treadmill exercise and coronary angioplasty, or nuclear medicine image and coronary angioplasty.

c: Included hospitalized patients only.

d: Gastrointestinal bleeding was defined as having operations of panendoscopy.

e: Non-specific type of operations on gastrointestinal bleeding.

f: Previous antithrombotic treatment was defined 90 days before index AF (including index admission date).

Trends over time of the various antithrombotic drug used between 1999 and 2010 are shown in [Fig 1](#pone.0125257.g001){ref-type="fig"}. As time progressed, warfarin usage increased significantly, from 13.5% in 2000 to 27.6% in 2010. Aspirin usage decreased between 2000 (65.4%) and 2010 (48.5%). Dual and triple therapy use remained relatively stable across the time period.

![Trends of various antiplatelet and anticoagulant agent usages during the study period, 1999--2010.](pone.0125257.g001){#pone.0125257.g001}

During a median 3.2 (interquartile range, 1.05--6.54) years' follow-up period, 1009 cases experienced bleeding events, whilst 224 hemorrhagic stroke and 1642 ischemic stroke events were recorded. The diagnostic image study has been performed by computed tomography (89%) and magnetic resonance image (26%). The incidence rates and associated risk estimates were listed in [Table 2](#pone.0125257.t002){ref-type="table"} and shown in [Fig 2](#pone.0125257.g002){ref-type="fig"}.

![Relative risks for the risk of bleeding (A), hemorrhagic stroke (B), and ischemic stroke (C), associated with the use of warfarin, aspirin, clopidogrel, and combinations of these drugs in the study patients.\
CI indicates confidence interval.](pone.0125257.g002){#pone.0125257.g002}

10.1371/journal.pone.0125257.t002

###### Incidence rate and relative risks, 95% confidence intervals of events associated with anticoagulant and antiplatelet.

![](pone.0125257.t002){#pone.0125257.t002g}

                                                         Non-exposed                 Antiplatelet                Warfarin and antiplatelet   Warfarin \[reference\]
  ------------------------------------------------------ --------------------------- --------------------------- --------------------------- ------------------------
  **Bleeding**                                                                                                                               
      No. of events                                      261                         582                         33                          133
      Person-years of follow-up                          5800                        28333                       745                         4672
      Incidence rate/1000 person-years                   45.00                       20.54                       44.32                       28.47
      Relative risk (95% confidence interval), p value                                                                                       
          Unadjusted                                     1.63(1.32--2.02), 0.001     0.86(0.71--1.31),0.15       1.88(1.27--2.78), 0.043     1
          Adjusted, Model 1^a^                           1.45(1.17--1.80), \<0.001   0.59(0.49--0.71), \<0.001   1.33(0.91--1.94), 0.20      1
  **Hemorrhagic stroke**                                                                                                                     
      No. of events                                      51                          123                         13                          37
      Person-years of follow-up                          5883                        29465                       778                         4805
      Incidence rate/1000 person-years                   8.67                        4.17                        16.71                       7.70
      Relative risk (95% confidence interval), p value                                                                                       
          Unadjusted                                     1.03(0.67--1.59), 0.86      0.53(0.37--0.77), \<0.001   2.09(1.11--3.93), 0.031     1
          Adjusted, Model 1^a^                           1.02(0.66--1.57), 0.86      0.52(0.36--0.75), \<0.001   2.03(1.08--3.83), 0.011     1
  **Ischemic stroke**                                                                                                                        
      No. of events                                      370                         1085                        40                          147
      Person-years of follow-up                          6239                        26367                       516                         3942
      Incidence rate/1000 person-years                   59.30                       41.15                       77.58                       37.29
      Relative risk (95% confidence interval), p value                                                                                       
          Unadjusted                                     1.36(1.12--1.65), 0.003     1.08(0.91--1.27), 0.50      1.97(1.39--2.79), \<0.001   1
          Adjusted, Model 1^a^                           1.33(1.09--1.61), 0.003     1.05(0.89--1.25), 0.50      1.90(1.34--2.70), \<0.001   1

Bleeding: Model 1 was adjusted for age, sex, comorbidities (Ischemic heart, Hypertension, Ischemic stroke, Heart Failure, Diabetes, Liver disease, Renal failure, Malignancy, Bleeding, Aspirin, Warfarin and Clopidogrel) were defined before index AF (including index admission date).

Hemorrhagic stroke: Model 1 was adjusted for sex, comorbidities (Ischemic heart, Hypertension, Ischemic stroke, Liver disease, Renal failure, Bleeding, Aspirin, Warfarin and Clopidogrel) were defined before index AF (including index admission date).

Ischemic stroke: Model 1 was adjusted for sex, comorbidities (Ischemic heart, Hypertension, Ischemic stroke, Heart Failure, Diabetes, Liver disease, Renal failure, Malignancy, Aspirin, Warfarin and Clopidogrel) were defined before index AF (including index admission date).

Comorbidity was defined as presence if the disease was diagnosed two years before the index date.

Relation to risk of bleeding and hemorrhagic stroke and therapy {#sec011}
---------------------------------------------------------------

Compared with those treated with warfarin (reference treatment), patients on antiplatelet drugs had a lower risk of bleeding (adjusted RR, 0.59, 95% CI, 0.49--0.71, p\<0.001) and hemorrhagic stroke (RR, 0.52, 95% CI, 0.36--0.75, p\<0.001) \[[Table 2](#pone.0125257.t002){ref-type="table"}\]. Patients with combination therapy had a non-statistically significant higher risk of bleeding (RR, 1.33, 95%, 0.91--1.94, p = 0.20) and an appreciably elevated risk of hemorrhagic stroke (RR, 2.03, 95% CI, 1.08--3.83, p = 0.011). Patients taking no antithrombotic treatment had a higher risk of bleeding (RR, 1.45, 95% CI, 1.17--1.80, p\<0.001), whereas no difference in incidence of hemorrhagic stroke was seen between warfarin group and no antithrombotic therapy group.

[Table 3](#pone.0125257.t003){ref-type="table"} shows results of analyses stratified by the HAS-BLED score. As expected, the bleeding risk increased with increasing HAS-BLED score. Patients on antiplatelet drugs were at a consistently lower risk for bleeding compared to the warfarin group irrespective of HAS-BLED strata (p values in each strata, 0.002 for low risk; \<0.001 for intermediate risk; 0.004 for high risk). RRs of bleeding was 0.37 (95% CI, 0.19--0.69, p = 0.002) for the low risk stratum, and 0.70(95% CI, 0.55--0.89, p = 0.004) for the high risk stratum. Compared to the warfarin group, patients in the intermediate and high bleeding risk strata who were taking no antithrombotic drugs were at higher risk for bleeding (RR, 2.44, 95% CI, 1.84--3.23, p\<0.001 for HAS-BLED ≥3).

10.1371/journal.pone.0125257.t003

###### Incidence rate and relative risks, 95% confidence intervals of events associated with anticoagulant and antiplatelet within different risk strata.

![](pone.0125257.t003){#pone.0125257.t003g}

                                                    Non-exposed   Antiplatelet                Warfarin and antiplatelet   Warfarin \[reference\]                                                          
  ------------------------------------------------- ------------- --------------------------- --------------------------- --------------------------- ----------- --------------------------- ----------- -----
  **Categorization of Bleeding risk by HAS-BLED**                                                                                                                                                         
      Low (0--1)                                    38(11.9)      0.84(0.47--1.50), 0.56      21(4.8)                     0.37(0.19--0.69), 0.002     3(24.7)     1.78(0.52--6.07), 0.36      17(12.5)    1.0
      Intermediate (2)                              78(63.2)      1.85(1.26--2.74), 0.002     144(16.9)                   0.54(0.38--0.78), \<0.001   6(31.6)     1.03(0.44--2.43), 0.95      39(30.5)    1.0
      High (\> = 3)                                 145(104.7)    2.44(1.84--3.23), \<0.001   417(27.0)                   0.70(0.55--0.89), 0.004     24(55.4)    1.43(0.91--2.27), 0.12      77(37.9)    1.0
  **Categorization of risk of ischemic stroke**                                                                                                                                                           
  **CHADS** ~**2**~ **, classical**                                                                                                                                                                       
      Low (0)                                       52(18.7)      0.63(0.41--0.98), 0.034     140(21.0)                   0.81(0.56--1.17), 0.25      8(69.9)     2.62(1.21--5.63), \<0.001   36(25.3)    1.0
      Intermediate (1--2)                           124(60.4)     1.58(1.13--2.19), 0.007     428(38.3)                   1.14(0.85--1.53), 0.37      11(130.2)   3.75(1.36--10.38), 0.011    51(33.5)    1.0
      High (\>2)                                    194(110.5)    1.64(1.23--2.18), \<0.001   517(60.4)                   0.98(0.76--1.27), 0.89      21(200.3)   2.91(1.06--7.99), 0.039     60 (66.2)   1.0
  **CHADS** ~**2**~ **2, revised**                                                                                                                                                                        
      Low (0)                                       52(18.7)      0.63(0.41--0.98), 0.034     140(21.0)                   0.81(0.56--1.17), 0.25      8(69.9)     2.62(1.21--5.63), \<0.001   36(25.3)    1.0
      Intermediate (1)                              53 (44.9)     1.32(0.85--2.05), 0.22      221(32.7)                   0.98(0.68--1.41), 0.90      6(47.5)     1.39(0.19--10.20), 0.74     33(33.9)    1.0
      High (\> = 2)                                 265(109.4)    1.66(1.29--2.12), \<0.001   724(59.1)                   1.07(0.86--1.34), 0.55      26(220.5)   3.94(1.82--8.52), \<0.001   78(54.8)    1.0
  **CHA** ~**2**~ **DS** ~**2**~ **-VASc**                                                                                                                                                                
      Low (0)                                       18(15.3)      0.72(0.35--1.50), 0.30      40(13.9)                    0.75(0.40--1.40), 0.28      3(46.1)     2.57(0.73--9.04), 0.087     13(18.3)    1.0
      Intermediate (1)                              35(20.9)      0.62(0.36--1.06), 0.10      107(23.4)                   0.82(0.52--1.28), 0.50      6(82.7)     2.74(1.11--6.73), 0.021     23(28.1)    1.0
      High (\>1)                                    317(78.7)     1.62(1.30--2.02), \<0.001   938(51.3)                   1.07(0.88--1.31), 0.63      31(84.2)    1.69(1.14--2.52), \<0.001   111(47.5)   1.0

Abbreviations: CI, confidence interval; RR, relative risk.

\*Incidence rate/1000 person-years

The detailed breakdown by actual therapy shown in [Fig 2](#pone.0125257.g002){ref-type="fig"} shows that compared to warfarin (reference), aspirin was associated with less bleeding. However, bleeding risk was not significantly different for other categories of drug exposures.

Relation to risk of ischemic stroke and therapy {#sec012}
-----------------------------------------------

When compared with patients on warfarin, those patients on antiplatelet drugs had a similar risk (RR 1.05, 95% CI, 0.89--1.25, p = 0.50), whilst the no antithrombotic therapy (RR 1.33, 95%CI, 1.09--1.61, p = 0.003) and combination therapy had a significantly higher risk (RR 1.90, 95% CI, 1.34--2.70, p\<0.001) \[[Table 2](#pone.0125257.t002){ref-type="table"}\].

As expected, there was increasing stroke risk with increasing risk strata of the CHADS~2~ and CHA~2~DS~2~-VASc scores \[[Table 3](#pone.0125257.t003){ref-type="table"}\]. For the low risk strata based on the CHA~2~DS~2~-VASc score, patients taking no antithrombotic therapy or antiplatelet drugs were at similar risk for ischemic stroke, when compared to those on warfarin as the reference treatment (RR, 0.75, 95% CI, 0.40--1.40, p = 0.28 for antiplatelet drugs, RR, 0.72, 95% CI, 0.35--1.50, p = 0.30 for no therapy). For the high risk strata, patients taking no antithrombotic therapy and on combination therapy had a higher risk for ischemic stroke, compared with those on warfarin (RR, 1.62, 95% CI, 1.30--2.02, p\<0.001 for no therapy; RR, 1.69, 95% CI, 1.14--2.52, p\<0.001 for combination therapy); however, patients taking antiplatelet drugs had a similar risk for ischemic stroke (RR, 1.07, 95% CI, 0.88--1.31, p = 0.63). A similar pattern was evident when analyzed by the CHADS~2~ score (classical or revised).

The detailed breakdown by actual therapy shown in [Fig 2](#pone.0125257.g002){ref-type="fig"} shows that compared to warfarin (reference treatment), the use of aspirin and aspirin+clopidogrel had similar risk of ischemic stroke, whilst stroke risk was increased with warfarin+aspirin, with a trend for warfarin+clopidogrel.

Discussion {#sec013}
==========

In this study of a large national representative cohort of AF patients from Taiwan, we show for the first time that antiplatelet therapy had no significant difference in ischemic stroke risk to warfarin, whilst combination therapy was associated with higher risks. For hemorrhagic stroke and bleeding, aspirin had a lower risk compared to warfarin, whilst combination therapy conferred a higher risk. These data are consistent with the poor efficacy and safety of warfarin in Asian patients, and offers important opportunities for improved stroke prevention with novel OACs.

A metaanalysis of clinical trial data has shown that adjusted dose anticoagulant therapy compared to control reduces stroke in AF by 64% and all cause mortality by 26%, and that warfarin was more protective than aspirin\[[@pone.0125257.ref021]\]. However, uncertain factors, such as genetics, dietary and drug factors make the adjustment of warfarin dosage unpredictable\[[@pone.0125257.ref017]\]. Our study clearly demonstrates antiplatelet usage had a lower risk for bleeding and hemorrhagic stroke, compared with warfarin, consistent with older trial data in Western population\[[@pone.0125257.ref021]\].

Interestingly we found that patients without any antithrombotic therapy in the high risk strata had a higher risk for bleeding, as well as ischemic stroke, compared to warfarin use. This is inconsistent with large observational data in USA and Swedish cohorts where compared with no warfarin use, patients treated with warfarin had a lower risk for ischemic stroke and hemorrhage\[[@pone.0125257.ref022]--[@pone.0125257.ref024]\]. Residual confounding may explain this, representing associated comorbidities, or risk factors for bleeding leading to non-prescription of OAC.

A population-based elderly cohort based on 125195 elderly patients (\> = 66 years old) with AF in Ontario showed the warfarin therapy was associated an overall rate of 3.8 per 100 person-year for bleeding, and the rates of bleeding increased from 1.8 in the low stratum of CHADS~2~ to 6.7 per 100 person-year in the CHADS~2~ scores of 4 or greater\[[@pone.0125257.ref025]\]. Our results showed similar bleeding event rates by HAS-BLED scores, which has recently been shown to be a better predictor for serious bleeding compared to the CHADS~2~ and CHA~2~DS~2~-VASc scores\[[@pone.0125257.ref026],[@pone.0125257.ref027]\].

Importantly, racial difference for drug susceptibility may be evident, especially for warfarin. Indeed, non-white patients had a higher risk for warfarin-related hemorrhagic stroke risk, and Asian population in particular have a higher risk for warfarin-related intracranial hemorrhage (relative risk,4.06, 95% CI, 2.47--6.65)\[[@pone.0125257.ref028]\]. Also, Asian patients with AF may do badly on warfarin compared to non-Asian patients, with higher rates of stroke, hemorrhagic stroke, major bleeding and intracranial bleeding\[[@pone.0125257.ref029]\]. Our data are also consistent with a small study by Guo et al\[[@pone.0125257.ref019]\], which showed antiplatelet drugs and warfarin had a similar risk of stroke/thromboembolism.

Nonetheless, efficacy and safety whilst on warfarin is highly dependent upon the quality of anticoagulation control, as reflected by average time in therapeutic range (TTR)\[[@pone.0125257.ref015],[@pone.0125257.ref016],[@pone.0125257.ref030]\]. For warfarin, this is established as an INR of 2.0--3.0, and an average TTR of \>70% is recommended in guidelines\[[@pone.0125257.ref031]\]. Unfortunately, our dataset does not have detailed TTR data, but we know from other published studies that the average TTR for warfarin is low, for example, being only 44% in the RE-LY trial\[[@pone.0125257.ref032]\]. Also, there is the perception that an INR 1.6--2.6 is best for older patients, and this may contribute to the stroke rates seen on warfarin, which appears no different to those on aspirin\[[@pone.0125257.ref033]\]. Herbal medicines are commonly used in our population which may also influence TTR status\[[@pone.0125257.ref034]\]. Nonetheless, our study shows a progressive increase in use of warfarin among the Taiwanese patients over time, although usage rates are still low when compared with Danish cohort (36.6%)\[[@pone.0125257.ref023]\].

The strengths of our study included a large population-based follow-up study and the integrated details of prescription records such as the drug used, dosages, days of supply dispensed from database. The health insurance program in Taiwan covers more than 99% of the adult population, and the cohort was a representative sample of population of Taiwan. Several studies based on the cohort showed that the score systems of CHADS~2~ and CHA~2~DS~2~-VASc were applicable in Taiwan\[[@pone.0125257.ref008],[@pone.0125257.ref035]\], and the results were compatible with a community based cohort \[[@pone.0125257.ref005],[@pone.0125257.ref036]\].

Limitations {#sec014}
-----------

First, the history of AF prior to 1996 was unknown, but patients with any record of AF before 1999 were excluded to reduce the possibility of including prevalent cases. Second, the validity of diagnosis of bleeding and stroke events may influence on our results, even though the accuracy of recording stroke diagnoses and prescriptions in NHIRD was high. Third, we lacked data for lifestyle information such as weight, drinking, or smoking status in this cohort. Finally, no data of adherence to the drug usage was obtained, nor TTR data, even we used time dependent covariate model to handle the exposure status. Poor adherence with various drug treatments may confound the estimation of bleeding and stroke risk.

In conclusion, in this study of a large national representative cohort from Taiwan, we show for the first time that antiplatelet therapy had no significant difference in ischemic stroke risk to warfarin, whilst for bleeding, aspirin had a lower risk compared to warfarin. This may reflect poor anticoagulation control, highlighting opportunities for improved stroke prevention with alternative strategies, such as the novel OACs.
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